CY1117691T1 - Υπερκορεσμενο ενεσιμο διαλυμα ακεταμινοφαινης για νωτιαια χορηγηση - Google Patents

Υπερκορεσμενο ενεσιμο διαλυμα ακεταμινοφαινης για νωτιαια χορηγηση

Info

Publication number
CY1117691T1
CY1117691T1 CY20161100584T CY161100584T CY1117691T1 CY 1117691 T1 CY1117691 T1 CY 1117691T1 CY 20161100584 T CY20161100584 T CY 20161100584T CY 161100584 T CY161100584 T CY 161100584T CY 1117691 T1 CY1117691 T1 CY 1117691T1
Authority
CY
Cyprus
Prior art keywords
solution
acutaminofein
supplementary
local administration
acetaminophen
Prior art date
Application number
CY20161100584T
Other languages
English (en)
Inventor
Augusto Mitidieri
Elisabetta Donati
Nicola Caronzolo
Original Assignee
Sintetica S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46690603&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1117691(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sintetica S.A. filed Critical Sintetica S.A.
Publication of CY1117691T1 publication Critical patent/CY1117691T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Η παρούσα εφεύρεση αναφέρεται σε ένα ενέσιμο υδατικό διάλυμα ακεταμινοφαίνης για χρήση στη θεραπεία ή στην πρόληψη του πόνου μέσω νωτιαίας χορήγησης, όπου το εν λόγω ενέσιμο διάλυμα ακεταμινοφαίνης είναι υπερκορεσμένο. Σε ορισμένες ενσωματώσεις, το ενέσιμο υδατικό διάλυμα ακεταμινοφαίνης χορηγείται ταυτόχρονα, ξεχωριστά ή διαδοχικά με ένα τοπικό αναισθητικό μέσω νωτιαίας χορήγησης.
CY20161100584T 2012-06-29 2016-06-28 Υπερκορεσμενο ενεσιμο διαλυμα ακεταμινοφαινης για νωτιαια χορηγηση CY1117691T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT001154A ITMI20121154A1 (it) 2012-06-29 2012-06-29 Soluzione iniettabile di acetaminofene per la somministrazione spinale
PCT/IB2013/055277 WO2014002042A1 (en) 2012-06-29 2013-06-27 Injectable supersaturated acetaminophen solution for spinal administration

Publications (1)

Publication Number Publication Date
CY1117691T1 true CY1117691T1 (el) 2017-05-17

Family

ID=46690603

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20161100584T CY1117691T1 (el) 2012-06-29 2016-06-28 Υπερκορεσμενο ενεσιμο διαλυμα ακεταμινοφαινης για νωτιαια χορηγηση

Country Status (44)

Country Link
US (2) US11344517B2 (el)
EP (1) EP2874602B1 (el)
JP (1) JP5876620B2 (el)
KR (1) KR102118227B1 (el)
CN (1) CN104487051B (el)
AP (1) AP2014008152A0 (el)
AR (1) AR091633A1 (el)
AU (1) AU2013282753B2 (el)
BR (1) BR112014032818B1 (el)
CA (1) CA2876801C (el)
CL (1) CL2014003536A1 (el)
CO (1) CO7240357A2 (el)
CR (1) CR20150036A (el)
CU (1) CU20140150A7 (el)
CY (1) CY1117691T1 (el)
DK (1) DK2874602T3 (el)
DO (1) DOP2014000302A (el)
EA (1) EA028909B1 (el)
EC (1) ECSP15000500A (el)
ES (1) ES2578012T3 (el)
GE (1) GEP201706689B (el)
HR (1) HRP20160706T1 (el)
HU (1) HUE029431T2 (el)
IL (1) IL236423A (el)
IT (1) ITMI20121154A1 (el)
MA (1) MA37811B1 (el)
MD (1) MD4537C1 (el)
ME (1) ME02431B (el)
MX (1) MX369264B (el)
MY (1) MY169251A (el)
NI (1) NI201400147A (el)
NZ (1) NZ703829A (el)
PE (1) PE20150331A1 (el)
PH (1) PH12015500178B1 (el)
PL (1) PL2874602T3 (el)
PT (1) PT2874602T (el)
RS (1) RS54844B1 (el)
SG (2) SG10201704482YA (el)
SI (1) SI2874602T1 (el)
SM (1) SMT201600248B (el)
TN (1) TN2014000526A1 (el)
UA (1) UA117101C2 (el)
WO (1) WO2014002042A1 (el)
ZA (1) ZA201409478B (el)

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69427728T2 (de) * 1993-04-14 2002-05-08 Nippon Oxygen Co Ltd Vorrichtung zur herabsetzung vom gelöstem sauerstoff
US6171298B1 (en) * 1996-05-03 2001-01-09 Situs Corporation Intravesical infuser
FR2751875B1 (fr) 1996-08-05 1998-12-24 Scr Newpharm Nouvelles formulations liquides stables a base de paracetamol et leur mode de preparation
FR2809619B1 (fr) 2000-06-06 2004-09-24 Pharmatop Nouvelles formulations aqueuses de principes actifs sensibles a l'oxydation et leur procede d'obtention
DE10112325A1 (de) * 2001-03-13 2002-10-02 Fresenius Kabi De Gmbh Lagerstabile Fertiginfusionslösungen des Paracetamols
HUP0402549A3 (en) * 2001-12-18 2006-01-30 Tseti Ioulia Parenteral composition of paracetamol
FR2851164B1 (fr) 2003-02-14 2005-04-22 Xuan Tho Nguyen Formulation liquide injectable de paracetamol
DE102005037653A1 (de) * 2005-08-05 2007-02-15 Theraselect Gmbh Stabile, flüssige Formulierung von Paracetamol
CA2628806C (en) * 2006-07-18 2012-08-21 Genfarma Laboratorio S.L. Injectable liquid paracetamol formulation
CN101015542A (zh) * 2007-02-13 2007-08-15 天津生机集团有限公司 家畜用复方对乙酰氨基酚注射液及其制备方法
MD3528G2 (ro) * 2007-09-28 2008-11-30 Сергей ШАНДРУ Metodă de anestezie spinală continuă la pacienţii în etate
US9399012B2 (en) * 2007-11-13 2016-07-26 Mallinckrodt Ip Reduced dose intravenous acetaminophen
US20110015273A1 (en) 2008-01-17 2011-01-20 Rajnarayana Kandhagatla Stable pharmaceutical aqueous compositions
WO2009143558A1 (en) 2008-05-26 2009-12-03 Silphion Pty Limited Injectable formulations
EP2243477A1 (de) 2009-04-22 2010-10-27 Fresenius Kabi Deutschland GmbH Paracetamol zur parenteralen Verabreichung
JP2013006770A (ja) 2009-10-09 2013-01-10 Ssp Co Ltd アセトアミノフェン含有経口液剤
CN102958519B (zh) * 2010-06-30 2016-01-13 特罗伊卡药品有限公司 包含扑热息痛的药物组合物及其制备方法

Also Published As

Publication number Publication date
IL236423A (en) 2017-07-31
PH12015500178A1 (en) 2015-04-06
HRP20160706T1 (hr) 2016-08-12
EA201500065A1 (ru) 2015-10-30
AR091633A1 (es) 2015-02-18
PT2874602T (pt) 2016-07-13
US11344517B2 (en) 2022-05-31
DOP2014000302A (es) 2015-03-15
ES2578012T3 (es) 2016-07-20
PL2874602T3 (pl) 2016-10-31
EA028909B1 (ru) 2018-01-31
DK2874602T3 (en) 2016-07-04
MX2014015402A (es) 2015-06-17
UA117101C2 (uk) 2018-06-25
HUE029431T2 (en) 2017-03-28
PH12015500178B1 (en) 2015-04-06
PE20150331A1 (es) 2015-03-07
BR112014032818A2 (pt) 2017-06-27
MD4537B1 (ro) 2017-12-31
AU2013282753B2 (en) 2017-03-02
IL236423A0 (en) 2015-02-26
EP2874602B1 (en) 2016-03-30
NZ703829A (en) 2016-06-24
CR20150036A (es) 2015-03-13
MD4537C1 (ro) 2018-07-31
RS54844B1 (sr) 2016-10-31
BR112014032818B1 (pt) 2022-06-14
WO2014002042A1 (en) 2014-01-03
CN104487051A (zh) 2015-04-01
SI2874602T1 (sl) 2016-09-30
SG11201408479WA (en) 2015-01-29
GEP201706689B (en) 2017-06-26
CO7240357A2 (es) 2015-04-17
AP2014008152A0 (en) 2014-12-31
MA37811B1 (fr) 2017-07-31
US20150148379A1 (en) 2015-05-28
MD20140138A2 (ro) 2015-06-30
MA37811A1 (fr) 2016-10-31
US20160128955A1 (en) 2016-05-12
EP2874602A1 (en) 2015-05-27
ECSP15000500A (es) 2015-11-30
ITMI20121154A1 (it) 2013-12-30
ME02431B (me) 2016-09-20
SMT201600248B (it) 2016-08-31
CL2014003536A1 (es) 2015-05-08
CU20140150A7 (es) 2015-10-27
TN2014000526A1 (en) 2016-03-30
JP2015522004A (ja) 2015-08-03
JP5876620B2 (ja) 2016-03-02
CN104487051B (zh) 2017-12-12
NI201400147A (es) 2015-04-13
SG10201704482YA (en) 2017-07-28
MX369264B (es) 2019-11-04
CA2876801A1 (en) 2014-01-03
CA2876801C (en) 2020-11-03
AU2013282753A1 (en) 2015-02-05
MY169251A (en) 2019-03-19
KR102118227B1 (ko) 2020-06-03
ZA201409478B (en) 2016-01-27
KR20150027160A (ko) 2015-03-11

Similar Documents

Publication Publication Date Title
CY1124298T1 (el) Φενφλουραμινη για χρηση στην θεραπευτικη αντιμετωπιση του συνδρομου dravet
CY1121150T1 (el) Νευροδραστικα 19-αλκοξυ-17-υποκατεστημενα στεροειδη, χρησιμα σε μεθοδους θεραπειας
CY1120832T1 (el) Τροποποιητες πυρηνικης μεταφορας και χρησεις αυτων
CY1125290T1 (el) Εφαρμογη r-κεταμινης και αλατος αυτης ως φαρμακα
CY1124000T1 (el) Υποκατεστημενες 5-φθορο-1η-πυραζολοπυριδινες σε κρυσταλλικη μορφη
CY1122648T1 (el) Διαδικασια για την παρασκευη συνθεσεων που περιεχουν υαλουρονικο οξυ και υδροχλωρικη μεπιβακαϊνη
CY1120975T1 (el) Συστημα αποθεματος που περιλαμβανει οξικη γλατιραμερη
CY1119676T1 (el) Συνθεσεις και μεθοδοι για τη θεραπεια του καρκινου
BR112016014410A2 (pt) terapia de combinação com vacina de neoantígeno
CR20140410A (es) Esketamina para el tratamiento de la depresión refractaria al tratamiento o resistente al tratamiento
BR112015025354A2 (pt) compostos di-hidropirido-pirimidínicos como inibidores de autotaxina
EA201691320A1 (ru) Способы лечения пациентов с гиперхолестеринемией, которая устойчива к терапии умеренными дозами статинов
AR099569A1 (es) Derivados de insulina y los usos médicos de estos
GT201500168A (es) Polipéptidos estabilizados del factor de crecimiento tipo insulina
DOP2016000170A (es) Compuestos derivados de hidroxiformamida y usos del mismo
CY1122899T1 (el) Υδατικη συσταση περιλαμβανουσα παρακεταμολη και ιβουπροφαινη
CY1119413T1 (el) Μεθοδος για την παραγωγη και τη χρηση ενος συμπολυμερους νατριουχου καρβοξυμεθυλοκυτταρινης και γκοσυπολης
CY1117831T1 (el) Θεραπεια συνδυασμου για τη θεραπευτικη αγωγη του καρκινου του μαστου
CY1123982T1 (el) Θεραπευτικη αγωγη για το πολλαπλο μυελωμα (μμ)
BR112015022825A2 (pt) métodos de diagnóstico, seleção e tratamento de doenças e condições causadas por ou associadas a metanógenos
CY1122042T1 (el) Συνθεση για χρηση στη θεραπεια του πονου που σχετιζεται με μεσοσπονδυλιο δισκο
UY31646A1 (es) Uso de fenilimidazolidinas sustituidas para producir medicamentos para el tratamiento del síndrome metabólico
CY1117579T1 (el) Παραγωγα φαινυλιου-γουανiδiνης
CY1123243T1 (el) Ενωση προερχομενη απο πυραζολινη και η χρηση τησσε ενα θεραπευτικο σχημα εβδομαδιαιας δοσολογησης εναντια στην φλεγμονη και τον πονο που προερχονται απο την εκφυλιστικη ασθενεια των αρθρωσεων στα θηλαστικα
EA201692371A1 (ru) 1h-1,8-нафтиридин-2-оны в качестве антипролиферативных соединений